Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Response Biomedical files for FDA clearance of RSV test
According to Response Biomedical, the RSV test is a qualitative immunochromatographic assay indicated for use as an in vitro diagnostic product to identify the presence of the RSV
According to Response Biomedical, the RSV test is a qualitative immunochromatographic assay indicated for use as an in vitro diagnostic product to identify the presence of the RSV
According to Verathon, the BVM 9500 measures both ultrasound-estimated bladder weight (UEBW) and bladder volume quickly and noninvasively to help diagnose bladder dysfunction, including benign prostatic hypertrophy and
Organic revenue growth, which includes the adjustments noted in the attached reconciliation, was flat as against to the first quarter of 2008. Revenue from continuing operations in the
Fiscal 2009 Outlook For fiscal 2009, Covidien now expects total operational growth to a range of 4% to 7%. Looking ahead for fiscal 2009, total Covidien net sales
Further, the company announced the senior management team for Abraxis Health, which will focus on biomarkers and personalized medicine. Soon-Shiong will assume the role of chief executive officer,
Umicore, a catalyst manufacturing company and Solvias, a technology provider have entered into a long term collaboration allowing quid pro quo access to each company’s respective asymmetric catalysis
Bayer, a producer of polymers and high-performance plastics, has reported a fall in the net income for the first quarter of 2009 by 44% to E425m compared to
Myriad Genetics, a developer of molecular diagnostic and therapeutic products, has launched OnDose, the company’s seventh molecular diagnostic product. According to Myriad Genetics, OnDose utilizes a technology to
For the first quarter of 2009, research and development expenses were $7.3, compared to $8.6 million for the same period in 2008. The decrease in research and development
Revenues of $26.3 million for the fourth quarter, down 1% over last year’s comparable quarter. Veterinary sales in North America of $16.5 million for the fourth quarter, up